Tag: Immunotherapy
-
Researchers Discover a Switch that Transforms Immune-Cold Tumors into Immune-Hot, Boosting Cancer Therapy
Transforming Immune-Cold Tumors into Immune-Active Targets Cancer research has long grappled with tumors that evade the body’s defenses. A recent study published in Nature Immunology, backed by the National Cancer Institute/NIH, reports a promising strategy to convert these immune-cold tumors into immune-hot ones. By priming the tumor environment with immune-activating signals, researchers observed a robust,…
-
EO2463 Wins FDA Fast Track for Follicular Lymphoma: A New Immunotherapy Hope
FDA Grants Fast Track Designation to EO2463 for Follicular Lymphoma The U.S. FDA has granted Fast Track designation to EO2463, a novel immunotherapy from Enterome, aimed at treating follicular lymphoma (FL), a typically slow-progressing yet incurable form of indolent non-Hodgkin lymphoma. The designation follows encouraging interim results from the ongoing phase 2 SIDNEY trial (NCT04669171)…
-
FDA Fast Track for EO2463 Immunotherapy Brings Hope for Follicular Lymphoma Patients
Overview: A New Immunotherapy Candidate in Follicular Lymphoma The FDA has awarded Fast Track designation to EO2463, Enterome’s novel immunotherapy designed for follicular lymphoma (FL), an indolent but often relapsing form of non-Hodgkin lymphoma. Grounded in promising interim data from the SIDNEY phase 2 trial, EO2463 represents a strategic effort to harness the immune system…
-
FDA Fast Track for EO2463 Immunotherapy Could Accelerate Follicular Lymphoma Treatment
FDA Grants Fast Track Designation to EO2463 for Follicular Lymphoma The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EO2463, a novel immunotherapy from Enterome, aimed at treating follicular lymphoma (FL), a common indolent form of non-Hodgkin lymphoma (NHL). This decision is based on encouraging interim results from the ongoing phase…
-
Checkpoint inhibitors aid tissue repair, offering new hope for chronic wounds
Summary: A new role for checkpoint inhibitors in tissue repair Checkpoint inhibitors, best known for unleashing the immune system against cancer, may also help heal damaged tissues. Researchers at the University of Zurich (UZH) have identified a previously unknown function of one such inhibitor, TIGIT: it promotes tissue repair after viral infection. The discovery, published…
-
QIMR Berghofer Passes Bill 2025: A New Era for Queensland Medical Research
Introduction: A Historic Turn for QIMR Berghofer The Queensland Institute of Medical Research (QIMR) Berghofer has crossed a major milestone with the passage of the QIMR Berghofer Bill 2025. Unveiled as the institute marks its 80th anniversary, the new Act repeals the 1945 framework and replaces it with a modern, governance-focused regime designed to accelerate…
-
Immunotherapy for HIV: Early PD-1 Treatment Shows Potential for Drug-Free Viral Control
Overview: A new immunotherapy approach in HIV Researchers report promising safety data from the first-in-human trial of an anti-PD-1 antibody, budigalimab, in people living with HIV. The study, published in Nature Medicine, explored whether a cancer immunotherapy could be used at low doses to augment the immune system’s ability to control HIV without daily antiretroviral…
-
Immunotherapy Trial: PD-1 Inhibitor Budigalimab Shows Potential for Drug-Free HIV Control
New Immunotherapy Approach Sparks Hope for HIV Management Researchers have taken a bold step in the hunt for HIV strategies that could reduce or even eliminate the need for daily antiretroviral therapy (ART). A first-in-human, randomized, placebo-controlled Phase 1b trial published in Nature Medicine explored budigalimab, a monoclonal antibody that targets the PD-1 protein, a…
-
Immunotherapy for HIV: Early Trials of Anti-PD1 Drug Budigalimab Suggest Drug-Free Viral Control
Immunotherapy Offers a New Avenue in HIV Management Researchers are cautiously optimistic about a novel immunotherapy approach that could one day reduce or even eliminate the need for daily HIV medications. In a first-in-human Phase 1b trial, budigalimab, a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) pathway, was tested in people…
-
QIMR Berghofer Bill 2025 Passes Parliament: A New Era for Queensland Medical Research
Overview: A landmark moment for QIMR Berghofer The Queensland Institute of Medical Research (QIMR) Bill 2025 has officially passed Parliament, marking a turning point for QIMR Berghofer as it enters a new era of governance, transparency, and agility. Originating as a 1945 Act, the legislative reform repeals the old framework and introduces a contemporary structure…